Venous Thromboembolism
From the Journals
Study gives bleeding risk estimates for VTE patients on anticoagulants
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
From the Journals
Prophylactic anticoagulation tied to lower death rate in COVID
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients...
From the Journals
Study suggests no added risk of blood clots in COVID-19 outpatients
From the Journals
New ASH guidelines: VTE prevention and treatment in cancer patients
Opinion
ASH guidelines for venous thromboembolism: What family physicians need to know
A recommendation regarding the use of DOACs may ease some of the burden of monitoring patients on long-term Coumadin.
Conference Coverage
VTE prophylaxis is feasible, effective in some high-risk cancer patients
Conference Coverage
Factor XI inhibitor–based anticoagulation strategies gain ground
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
Conference Coverage
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
Conference Coverage
Switching to riociguat effective for some patients with PAH not at treatment goal
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
Conference Coverage
Selexipag has no effect on daily activity in PAH patients
After 24 months of daily tracking, there was no benefit to increased daily activity for patients taking this drug.
Conference Coverage
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides